anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: CT perfusion is a valuable tool for evaluating cerebrovascular diseases, but its role in patients with hypoxic ischaemic encephalopathy is unclear. This study aimed to investigate 1) the patterns of cerebral perfusion changes that may occur early on after successful resuscitation, and 2) their correlation with clinical outcome to explore their value for predicting outcome.
METHODS: We conducted a retrospective analysis of perfusion maps from patients who underwent CT brain perfusion within 12 h following successful resuscitation. We classified the perfusion changes into distinct patterns. According to the cerebral performance category (CPC) score clinical outcome was categorised as favourable (CPC 1-2), or unfavourable (CPC 3-5).
RESULTS: A total of 87 patients were included of whom 33 had a favourable outcome (60.6% male, mean age 60 ± 16 years), whereas 54 exhibited an unfavourable outcome (59.3% male, mean age 60 ± 19 years). Of the patients in the favourable outcome group, 30.3% showed no characteristic perfusion changes, in contrast to the unfavourable outcome group where all patients exhibit changes in perfusion. Eighteen perfusion patterns were identified. The most significant patterns for prediction of unfavourable outcome in terms of their high specificity and frequency were hypoperfusion of the brainstem as well as coexisting hypoperfusion of the brainstem and thalamus.
CONCLUSION: This pilot study identified various perfusion patterns in patients after resuscitation, indicative of circulatory changes associated with post-cardiac-arrest brain injury. After validation, certain patterns could potentially be used in conjunction with other prognostic markers for stratifying patients and adjusting personalized treatment following cardiopulmonary resuscitation. Normal brain perfusion within 12 h after resuscitation is predictive of favourable outcome with high specificity.
The association between molluscum contagiosum and concomitant atopic dermatitis and its impact on clinical features and treatment outcomes remains unclear. This retrospective study, conducted in the paediatric dermatology clinic of a tertiary medical centre, aimed to compare molluscum patients with and without atopic dermatitis. A total of 615 children with molluscum were included, 13.17% of whom had atopic dermatitis. While the latter group exhibited higher lesion count and itchiness (p=0.026 and p=0.044, respectively), no significant differences were observed in average lesion diameter, ulceration, purulence, and erythema (p=0.239, p=0.730, p=0.682, and p=0.296, respectively). Both groups showed comparable responses to molluscum-specific and supportive treatments, with no distinct difference in outcomes or recurrence of visits. It was concluded that atopic dermatitis does not exacerbate molluscum morbidity, inflammation markers, treatment outcomes or recurrence rates.
PURPOSE:To adjust the discharge of various core substances from its microcapsule as desired by forming the capsule encapsulating core substances and high molecular substances with a capsule membrane obtained by coagulating colloidal particles with an electrolyte. CONSTITUTION:A core substance, a high molecular substance, a host compd. forming a clathrate, a reactive monomer and/or a prepolymer or the clathrate of the core substance are added to a dispersion (hydrosol) of colloidal particles in a dispersion medium, e.g. water. The dispersion is dispersed in an oily medium to form an emulsion and the colloidal particles in the emulsion are coagulated with an electrolyte to produce the microcapsule. Dyes, pigments, medicine, agricultural chemicals, perfumes, chemical products, adhesive, enzyme, biomass, etc., are used as the core substances. (alpha),(beta),(gamma)-cyclodextrin, cyclophane, crown ethers, etc., may be exemplified as the host for forming the core substance into a clathrate.
PURPOSE:To provide the titled additive which is an aqueous solution containing terpenes as main active deodorizing component, and is effective to actively deodorize the ill odor of cold permanent wave lotion without masking the odor with the smell of perfumery, etc. CONSTITUTION:Terpenes used mainly as raw materials of perfumery, preferably citral, limonene, cedrol, cineole (eucalyptus oil), etc. are used as the main deodorizing components of the objective additive. The additive is used preferably in the form of an aqueous emulsion, and the concentration of the terpene in the emulsion is preferably about 30-45% when terpene is used singly. The additive may be incorporated further with camphor oil, eucalyptus oil, etc. at a concentration of about 5-20wt%. EFFECT:It utilizes the deodorizing activities of terpenes, i.e. the molecular adsorptivity of terpene and the activity of terpene vapor to encapsulate the odorous fine particles.
The invention discloses a cactus tablet and a preparation method thereof. The cactus tablet comprises the following raw materials in parts by weight: 50 to 2000 parts of cactus, 10 to 400 parts of ligustrum lucidum, 10 to 400 parts of pseudostellaria root, 70 to 2000 parts of cyclodextrin, 70 to 2000 parts of skeleton material, 15 to 20 parts of bonding agent, 40 to 60 parts of diluent, 3 to 10 parts of flavoring agent, and 2 to 5 parts of lubricant. The cactus, ligustrum lucidum, and pseudostellaria root are compounded to generate a synergetic effect. The cactus tablet has a prominent effect of boosting qi and tonifying deficiency and can help fat people to lose weight. The cactus can also enhance the physique and endurance of vegetarian and weak people. According to the preparation method, the cactus is grinded and pulped, clastic enzyme is added to fully release the pharmacological active components, the extraction rate and utilization rate of pharmacological active components in cactus can be improved, then the extracts of ligustrum lucidum and pseudostellaria root are added, three traditional Chinese herbals generate a synergetic effect, and the pharmacologic effect is fully exerted.
FIELD: medicine, vaccine preparations. SUBSTANCE: invention relates to producing viral vaccine preparations in the capsulated form. Method involves multiplication of the measles virus on cellular substrate, collection of virus-containing liquid, removal of cellular detritus from the product and addition the stabilizing composition followed by lyophilization of the preparation. The collection of virus-containing liquid is carried out at virus titer 5.0-6.0 lg TCD 50/0.5 ml, not less, and at protein concentration 16 mcg/ml, not above. Sorbitol, sucrose, gelatose and peptone are added to virus-containing liquid as a stabilizing composition up to their final concentration in the mixture 0.8-1.2; 2.5-3.5; 2.5-3.5 and 2.5-3.5 wt.-% of each component of stabilizer, respectively. After lyophilization the dried virus-containing material is milled, placed into capsules and capsules are coated by an acid-resistant acetylphthalylcellulose-base envelope. Method ensures to prepare the live antimeasles vaccine in the capsulated form for oral use. EFFECT: broadened arsenal of vaccine preparations for treatment and prophylaxis of measles, use of the simple and efficient technical equipment. 1 tbl, 6 ex
Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula (1) or Formula (2). Currently preferred compounds, based on in vivo biological activity, are 4'adamantylbenzoate-1'-N-1,4-dihydroxybenzylamine and 4'-adamantylmethylbenzoate-1'-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.
PURPOSE:A skin drug for removing blotch, mole, wart, etc., obtained by dissolving a pressure-sensitive adhesive in an aqueous solution of an alkali caustic. CONSTITUTION:25-35pts.wt. pressure-sensitive adhesive (e.g., starch) is dissolved in 100pts.wt. of 5-20wt% aqueous solution of alkali (e.g., NaOH or KOH) caustic to give a skin drug. Since the alkali caustic shows destructive action by hydroxyl ion in the solution, the caustic has low effects if it is not applied to the skin as an aqueous solution. An aqueous solution of an alkali is apt to flow and causes inflammation on normal skin or mucosa when it is applied to part except part on which wart, etc., are formed, but the skin drug has viscosity, can be stuck fast to the affected part, so blotch, mole, wart, etc., can be completely removed. The drug is applied and in contact with the affected part preferably for 5-10min and application is carried out preferably 3-5 times daily.
Patients who fulfill all inclusion and none of the exclusion criteria after giving informed consent will be enrolled in the Validation study.

At enrollment, patients will receive a stroke nurse assessment in the Emergency Department (ED) and clinical information documented on an ACVS Assessment Form/SpecTRA Case Report Form. Patients will provide 6 mL of blood drawn into a purple-top EDTA tube that will be processed for proteomic analyses. These blood draws may or may not occur with the standard-of-care blood draw in the ED or stroke unit. Clinical orders include medical imaging (MRI +/- CT/CTA), cardiac monitoring (24hr +/- extended event monitoring). Patients will be referred by the attending ED physician to a stroke clinic for neurological consultation within 48 hours - 7 days, whereby diagnosis of (i) possible ACVS; (ii) definite ACVS or (iii) mimic will be made. At the stroke clinic a cognitive screening test will be administered either as part of usual clinical care by treating physicians, nurses, or a study coordinator. A re- assessment will be repeated at 90 days by phone. MRI will be reviewed initially for clinical interpretation at the neurological consultation for evidence of brain ischemia (DWI+) and later by neuro-radiologists for definitive diagnosis in study purposes. Final adjudication of TIA and aetiology will be done by the non-blinded principal investigators at each site based on diagnostic results plus 90-day and up to 2-year outcomes.
PURPOSE:The titled composition, obtained by blending a carboxyvinyl polymer with a neutralizing agent therefore, alcohol and water, having good feeling of use without smarting hemorrhoids, inflammations, wounds, etc., on the peripheries of the annus and capable of readily keeping the peripheries of the annus clean. CONSTITUTION:A composition obtained by blending (A) a carboxyvinyl polymer, preferably crosslinkable type water-soluble polyacrylic acid with (B) a neutralizing agent for the polymer, e.g. alkali metal hydroxide or carbonate or organic base, (C) ethyl alcohol or isopropyl alcohol and (D) water. The amounts of the above-mentioned ingredients based on the total composition are 0.1-1.0wt% ingredient (A) 0.5-25wt% ingredient (C). The blending ratio of the ingredients (B) to (A) is 0.1-40:1. The above-mentioned composition in a small amount is applied to tissue paper or toilet paper for use.
Several large-scale studies have measured plasma levels of the proteome in individuals with cardiovascular diseases (CVDs)1-7. However, since the majority of such proteins are interrelated2, it is difficult for observational studies to distinguish which proteins are likely to be of etiological relevance. Here we evaluate whether plasma levels of 2,919 proteins measured in 52,164 UK Biobank participants are associated with incident myocardial infarction, ischemic stroke or heart failure. Of those proteins, 126 were associated with all three CVD outcomes and 118 were associated with at least one CVD in the China Kadoorie Biobank. Mendelian randomization and colocalization analyses indicated that genetically determined levels of 47 and 18 proteins, respectively, were associated with CVDs, including FGF5, PROCR and FURIN. While the majority of protein-CVD observational associations were noncausal, these three proteins showed evidence to support potential causality and are therefore promising targets for drug treatment for CVD outcomes.
To provide a measuring device that facilitates understanding what exercise an exerciser should perform.SOLUTION: A measuring device 10 comprises a measurement unit 120 and a selection unit 140. The measurement unit 120 measures at least either a sugar concentration or a lipid concentration in a body fluid (e.g., blood) of an exerciser. The selection unit 140 selects either a first exercise or a second exercise with regard to a measurement result of the measurement unit 120 and outputs a selection result. The first exercise is, for example, an anaerobic exercise, and the second exercise is, for example, an aerobic exercise. Information to be output may be a concrete example of the anaerobic exercise or a concrete example of the aerobic exercise. The measuring device 10 is, for example, a portable device, but can be a stationary device.SELECTED DRAWING: Figure 1
The invention relates to a fennel soup integrative new dosage form preparation technology and a production method thereof. The fennel soup integrative new dosage form has the raw material compositions of the effective components by weight: 6 parts of fennel, 2 parts of szechwan Chinaberry fruit, 2 parts of dried orange peel, 7 parts of honey-fried licorice root and 1 part of fried salt. The production process comprises: ultrasonic air-flow crushing, alcohol water extraction, supersonic wave crushing extraction, water decoction condensation, ultrasonic spray drying, nanometer grinding, high pressure homogenization, nanoparticle preparation, etc. The invention emphasizes multi cooperation, multi targeting and other advantages embodying by utilizing nanometer carrier combination technology. After the large-scale production, the invention can greatly reduce production cost, greatly raise product quality, make medicament targeting and sustained and controlled release stronger. The new dosage form can be internal and external drug given at the same time, be taken respectively at four time ranges according to midnight-midday ebb flow and qi-blood flow rule, can be made into film forming agent and transdermal agent according to midnight-midday ebb flow and human body qi-blood flow rule respectively pasting on people different parts and can directly absorb through skins.
Many patients with bipolar disorder (manic-depressive illness) require more than one medication to control their symptoms. This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-groupd study to evalute the efficacy and safety of topiramate versus placebo as add-on therapy to lithium or valproate for the treatment of bipolar 1 disorder as an outpatient setting. These patients must already be taking either lithium or valproate for at least 6 weeks before the first visit and have been on the same dose of the mood stabilizer for at least 2 weeks before the first visit. Paitents will be randomized to receive either placebo or topiramate, an anti-seizure medication not approved for the treatment of bipolar disorder, in addition to their lithium or valporate. The study consists of 56-day titration (topiramate will be titrated up to 400mg per day or the maximum tolerated dose), 28-day continuation period, and 7 days of follow-up to taper off the medication. The study hypothesis is that topiramate will be more effective than placebo in the treatment of mania in type 1 bipolar disorder patients as measured by the Young Mania Rating Scale (YMRS) and will be well tolerated. YMRS is a questionnaire consisting of 11 items designed to assess severity of mania symptoms.

Patients will start taking topiramate 25 mg per day or placebo by mouth. Over the next 8 weeks, doses will be increased to up to 400 mg per day or to the maximum tolerated dose, whichever is lower. After the first 8 weeks, patients will stay at the established dose for the next 4 weeks.
The present invention provides the preparation methods of 12 White Phoenix Bolus of Black-bone Chickens and White Phoenix Bolus of Black-bone Chicken obtained, step to include：S1. Chinese yam is crushed；S2. boiling Gallus domesticlus brisson adds yam flour after well-done, obtains Chinese yam Gallus domesticlus brisson hybrid dry matter；S3. Radix Angelicae Sinensis and Rhizoma Chuanxiong are pre-processed；S4. plus complex enzyme is concentrated, drying gets dry extract with water decoction Radix Codonopsis, prepared rehmannia root and Radix Paeoniae Alba；S5. by preparing astragalus membranaceus, wine Fructus Schisandrae (processed), calcined oyster shell, deer horn glue, sweet wormwood, treated Radix Angelicae Sinensis and Rhizoma Chuanxiong mixing crush to obtain mixed powder；S6. mixing Chinese yam Gallus domesticlus brisson hybrid dry matter, dry cream and mixed powder crush, sieving, sterilizing obtains medicinal powder；S7. mixed powder, antioxidant, antistaling agent, disintegrant and refined honey, pharmacy ball；S8. pill drying, polishing obtain 12 White Phoenix Bolus of Black-bone Chickens.Medicinal material utilization rate of the present invention is high, effectively prevents the influence that medicinal material goes mouldy to product quality.12 White Phoenix Bolus of Black-bone Chicken stability obtained is good, and contamination rate is low, is easy to preserve.
The present invention provides a system and principles of laser photo-acoustic imaging and tomography. The basis for laser photo-acoustic tomography is the time resolved detection of laser induced transient stress waves, selectively generated in absorbing tissues of diagnostic interest. Such a technique allows to visualize absorbed light distribution in turbid biological tissues irradiated by short laser pulses. Laser photo-acoustic tomography can be used for detection of tissue pathological changes that result in increased concentration of various tissue chromophore such as hemoglobin or development of enhanced micro-circulation in diseased tissue. The invented technology combines the advantages of pulsed laser excitation with time resolved detection of acoustic transients. The invented technology can be used for determination of optical heterogeneities in biological tissues. These heterogeneities include blood vessels, tissue layers, abnormal tissues and damaged tissues with further reconstruction of 3D tomographic images of human organs or portions thereof.
OBJECTIVE: Frailty is more reliable than chronological age in predicting the effectiveness and tolerability of treatments in cancer patients. An increasing number of screening tools have been proposed, however none have received unanimous consent or been specifically designed for women with gynecological malignancies.This study's aim was to develop a clinical application of a screening tool to identify frail patients >70 years old diagnosed with either ovarian or endometrial cancers.
METHODS: A 20 item questionnaire was developed and administered to the cohort before surgery or neoadjuvant chemotherapy. A cut-off for frailty definition was determined by analyzing the correlation of questionnaire scores with the completion of treatments. The association between frailty and treatment related complications was assessed using a Chi-squared test for categorical variables and a t-test for continuous variables.
RESULTS: Our study included 100 patients, 50% diagnosed with endometrial cancer and 50% with ovarian cancer. A questionnaire score of 4 was the best cut-off for frailty definition (sensitivity 77%, specificity 100%). Surgical grade III and grade IV complications were observed only in frail patients (p=0.01) and hospitalization was significantly longer in frail women affected by ovarian cancer (p=0.01). Frail patients were more exposed to chemotherapy administration delay (p=0.0005), treatment discontinuation (p=0.001) and hematological toxicities, especially anemia ≥grade 2 (p=0.009) and thrombocytopenia any grade (p=0.0001).
CONCLUSION: With a cut-off score of 4, our tool can identify frail patients with significantly higher incidence of grade III-IV postoperative complications, length of stay, medical treatment discontinuation rates and hematological toxicities.
A method for radiolabeling protein such as antibody which is performed in a single reaction vessel. A sealed reaction vessel having a port for addition and withdrawal of reagents preferably by syringe is used. Reagents for coupling radioisotope to the protein are added to the vessel. For radioiodination procedures, vessels can be pre-coated with the iodine coupling agent iodogen. The protein and the radioisotope are then added to the vessel and the radiolabel reaction allowed to proceed. After the reaction is complete, a resin is added to the vessel to adsorb the uncoupled radioisotope. The entire reaction mixture is then withdrawn from the vessel and the resin is separated from the protein preferably by sterile filtration.
Molluscum contagiosum (MC) is a benign cutaneous viral infection commonly affecting children, sexually active adults, immunocompromised individuals, and patients on immunosuppressive therapy. Giant periorbital MC lesions with preseptal cellulitis are rare. We present 2 such pediatric cases. Case 1 was a 9-month-old boy with an enlarging left upper eyelid mass and preseptal cellulitis. MC was confirmed on histopathology, and surgical excision was curative. Case 2 was an 18-month-old girl with a right lower eyelid ulcerating mass and preseptal cellulitis. She was managed with antibiotics and surgical excision.